Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012–2017

Volume: 72, Issue: 3, Pages: 379 - 385
Published: Jan 14, 2020
Abstract
Background Daily oral pre-exposure prophylaxis (PrEP) is highly effective in preventing human immunodeficiency virus (HIV) infection if used adherently throughout periods of HIV risk. We estimated PrEP persistence among cohorts of persons with commercial or Medicaid insurance. Methods We analyzed data from the IBM MarketScan Research Database to identify persons aged 18–64 years who initiated PrEP between 2012 and 2017. We assessed PrEP...
Paper Details
Title
Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012–2017
Published Date
Jan 14, 2020
Volume
72
Issue
3
Pages
379 - 385
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.